Clinical trial · Interventional
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091
NCT00439608CI-TRIAL-00043456completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab,Paclitaxel, Carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
- interventionNames
- Drug: Cetuximab,Paclitaxel, Carboplatin
Primary outcomes (1)
- measure
- Reponse Rate at Time of Surgery by Tissue
- timeFrame
- within 30 days of last treatment
- description
- pathologic complete response rate at surgery
Secondary outcomes (1)
- measure
- Number of Participants With Grade 2 and/or 3 Rash in Patients With Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus, Gastroesophageal Junction, or Stomach.
- timeFrame
- baseline, then during treatment, about 5 weeks through 30 days post treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach. * Patients may have mediastinal, celiac adenopathy, peri-portal and regional gastric lymphadenopathy. * There must be no evidence of distant organ metastases. * No prior radiation for gastric or esophageal cancer. * Patients must be \> 18 years of age, and nonpregnant * Patients must have an ANC \> 1,500/ul, platelets \> 100,000/ul, creatinine \< 2 x upper limit normal (ULN) and bilirubin \< 1.5 x ULN, and AST \< 3 x ULN. * ECOG performance status 0-2. * Patients must not have significant infection or other coexistent medical condition that would preclude protocol therapy. * Female patients, must either be not of child bearing potential or have a negative pregnancy test within 7 days of starting study treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Pregnant or lactating females are not eligible. * All patients must sign informed consent Exclusion Criteria: Any of the following criteria will make the patient ineligible to participate in this study: * Acute hepatitis or AIDS. * Active or uncontrolled infection. * Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction. * Prior therapy which specifically and directly targets the EGFR pathway. * Prior severe infusion reaction to a monoclonal antibody. * Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).
References
Publications (0)
Data not yet available
No reference posted for this study.